Proteomics analysis reveals IGFBP2 as a candidate diagnostic biomarker for heart failure

Conclusion IGFBP2 is a new biomarker to diagnose HF which could be used to provide additional information to the NPs. Animals models will help in the evaluation of the putative IGFBP2 regulated mechanisms in HF. Clinical Trial Registration ClinicalTrials.gov NCT01024049.
Source: IJC Metabolic and Endocrine - Category: Endocrinology Source Type: research